SARS-CoV-2 Infection In Patients With Mastocytosis: An
EPICOVIDEHA Report

J 2023

SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report

CRISCUOLO, M.; J. SALMANTON-GARCIA; N. FRACCHIOLLA; G. DRAGONETTI; N. KHANNA et al.

Základní údaje

Originální název

SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report

Autoři

Vydání

Journal of Investigational Allergology and Clinical Immunology, BARCELONA, INTERASMA, 2023, 1018-9068

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Španělsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.700

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00133599

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Systemic mastocytosis; SARS-CoV-2; COVID-19; Malignancy; Treatment

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 3. 2024 10:33, Mgr. Tereza Miškechová

Anotace

V originále

Systemic mastocytosis (SM) is a rare hematological disease characterized by neoplastic proliferation of clonal mast cells (MCs). It involves the gastrointestinal tract, bone, liver, and spleen in addition to bone marrow and skin. The symptoms caused by release of MC mediators and organ infiltration can seriously affect quality of life and survival. Patients with SM are not expected to have a higher risk of infection by SARS-CoV-2; however, this risk can be augmented by comorbidities and impairment of organ function due to infiltration by MCs. Treatment of SM is based on different classes of drugs, which may have an impact on outcome in SARS-CoV-2 infection. However, no study has reported the determinants of outcomes in patients with SM and SARS-CoV-2 infection, according to concurrent treatment.

Citovat

CRISCUOLO, M.; J. SALMANTON-GARCIA; N. FRACCHIOLLA; G. DRAGONETTI; N. KHANNA; Barbora WEINBERGEROVÁ; M. SCHOENLEIN; M. MACHADO; J. LABRADOR; M. KOLDITZ; F. ITRI; Da Silva M. GOMES; V. BONUOMO; M. SCIUME; R Nunes RODRIGUES; S. GRAEFE; F. MARCHESI; O. A. CORNELY a L. PAGANO. SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report. Journal of Investigational Allergology and Clinical Immunology. BARCELONA: INTERASMA, 2023, roč. 33, č. 3, s. 225-227. ISSN 1018-9068. Dostupné z: https://doi.org/10.18176/jiaci.0845.

@article{2376677,
   author = {Criscuolo, M. and SalmantonandGarcia, J. and Fracchiolla, N. and Dragonetti, G. and Khanna, N. and Weinbergerová, Barbora and Schoenlein, M. and Machado, M. and Labrador, J. and Kolditz, M. and Itri, F. and Gomes, Da Silva M. and Bonuomo, V. and Sciume, M. and Rodrigues, R Nunes and Graefe, S. and Marchesi, F. and Cornely, O. A. and Pagano, L.},
   article_location = {BARCELONA},
   article_number = {3},
   doi = {https://doi.org/10.18176/jiaci.0845},
   keywords = {Systemic mastocytosis; SARS-CoV-2; COVID-19; Malignancy; Treatment},
   language = {eng},
   issn = {1018-9068},
   journal = {Journal of Investigational Allergology and Clinical Immunology},
   title = {SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report},
   url = {https://www.jiaci.org/summary/vol33-issue3-num2707},
   volume = {33},
   year = {2023}
}

TY  - JOUR
ID  - 2376677
AU  - Criscuolo, M. - Salmanton-Garcia, J. - Fracchiolla, N. - Dragonetti, G. - Khanna, N. - Weinbergerová, Barbora - Schoenlein, M. - Machado, M. - Labrador, J. - Kolditz, M. - Itri, F. - Gomes, Da Silva M. - Bonuomo, V. - Sciume, M. - Rodrigues, R Nunes - Graefe, S. - Marchesi, F. - Cornely, O. A. - Pagano, L.
PY  - 2023
TI  - SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report
JF  - Journal of Investigational Allergology and Clinical Immunology
VL  - 33
IS  - 3
SP  - 225-227
EP  - 225-227
PB  - INTERASMA
SN  - 10189068
KW  - Systemic mastocytosis
KW  - SARS-CoV-2
KW  - COVID-19
KW  - Malignancy
KW  - Treatment
UR  - https://www.jiaci.org/summary/vol33-issue3-num2707
N2  - Systemic mastocytosis (SM) is a rare hematological disease characterized by neoplastic proliferation of clonal mast cells (MCs). It involves the gastrointestinal tract, bone, liver, and spleen in addition to bone marrow and skin. The symptoms caused by release of MC mediators and organ infiltration can seriously affect quality of life and survival. Patients with SM are not expected to have a higher risk of infection by SARS-CoV-2; however, this risk can be augmented by comorbidities and impairment of organ function due to infiltration by MCs. Treatment of SM is based on different classes of drugs, which may have an impact on outcome in SARS-CoV-2 infection. However, no study has reported the determinants of outcomes in patients with SM and SARS-CoV-2 infection, according to concurrent treatment.
ER  -

CRISCUOLO, M.; J. SALMANTON-GARCIA; N. FRACCHIOLLA; G. DRAGONETTI; N. KHANNA; Barbora WEINBERGEROVÁ; M. SCHOENLEIN; M. MACHADO; J. LABRADOR; M. KOLDITZ; F. ITRI; Da Silva M. GOMES; V. BONUOMO; M. SCIUME; R Nunes RODRIGUES; S. GRAEFE; F. MARCHESI; O. A. CORNELY a L. PAGANO. SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report. \textit{Journal of Investigational Allergology and Clinical Immunology}. BARCELONA: INTERASMA, 2023, roč.~33, č.~3, s.~225-227. ISSN~1018-9068. Dostupné z: https://doi.org/10.18176/jiaci.0845.

Přehled o publikaci